VVUS Projected Dividend Yield

Vivus Inc ( NASDAQ : VVUS )

VIVUS is a pharmaceutical company with three approved therapies and one product candidate in active clinical development. PANCREAZE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Qsymia® (phentermine and topiramate extended release) is approved by FDA for chronic weight management. STENDRA® (avanafil) is approved by FDA for erectile dysfunction (ED) and by the European Commission under the trade name SPEDRA, for the treatment of ED in the European Union. VI-0106 (tacrolimus) is in active clinical development and is being studied in patients with pulmonary arterial hypertension.

20 YEAR PERFORMANCE RESULTS